- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Lilly's Zepbound remains physicians' favorite, even as oral obesity launches altar landscape | ||
| Fr | AbbVie's Skyrizi retakes edge in pharma's July ad spending league | ||
| Fr | Novo Nordisk makes Omnicom agency of record for US media buying | ||
| Fr | Fresenius Kabi recalls mislabeled morphine lot that could cause overdose death | ||
| Do | Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle | ||
| Do | Sarepta's new CEO Michael Severino faces critical milestones to prove growth | ||
| Do | Takeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful | ||
| Do | Sanofi asked to change Dupixent ads after Galderma challenge | ||
| Mi | AstraZeneca, CSPC to form joint venture for biologics manufacturing | ||
| Mi | Alcon survey spots gaps in teen eye care ahead of back-to-school season | ||
| Mi | Lilly's obesity pill Foundayo 'disappointed' in Q2, as injectables continue to boom | ||
| Mi | Novo CEO has 'no doubt' on eventual share price recovery as Wegovy pill continues to wow | ||
| Mi | Gilead's HIV PrEP franchise hits $1B quarterly sales, but analysts question Yeztugo durability | ||
| Mi | 'No discussions' ongoing for AstraZeneca-Bristol Myers merger: Reuters | ||
| Di | Amgen rides Repatha renaissance as cardio wins keep cholesterol med's momentum rolling | ||
| Di | As FDA makes Lipfendra poster child of CNPV pilot, Merck charts long-term path for first PCSK9 pill | ||
| Di | Drugmakers don't have 'duty to innovate', California court rules, backing Gilead in HIV drug litigation | ||
| Di | Pfizer unveils additional $2.5B in planned cost savings through 2029 | ||
| Di | J&J innovative medicine chief Jennifer Taubert to retire, handing reins to North America head | ||
| Di | 'Better every quarter': Bayer CEO stays course on turnaround plan as pharma sales underwhelm in Q2 | ||
| Di | Jazz to withdraw Zepzelca with FDA in second-line small cell lung cancer | ||
| Mo | In a first, Otsuka's Voyxact stabilizes IgAN patients' kidney function decline to normal levels | ||
| Mo | Curium strikes up to $8B deal for radiopharma rival Lantheus | ||
| Mo | Supernus, Indivior merge to create CNS-focused company and expand BD opportunities | ||
| Mo | Amgen says patient health data, IP stolen in cybersecurity breach |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.